Yes, Depakote is Available in an Intravenous Formulation
Yes, there is an intravenous formulation of valproate (marketed as Depacon), though Depakote itself refers specifically to the oral divalproex sodium formulation. The IV formulation contains valproate sodium and is FDA-approved and widely used in clinical practice 1.
Key Clinical Context
The distinction is important but often used interchangeably in practice:
- Depakote = oral divalproex sodium (delayed-release tablets, extended-release tablets, or sprinkle capsules)
- Depacon = intravenous valproate sodium
- Both convert to valproate ion, the active form 1
Clinical Applications of IV Valproate
IV valproate is recommended as a second-line agent for status epilepticus after benzodiazepines fail, with evidence showing comparable or superior efficacy to phenytoin 2. The 2014 Annals of Emergency Medicine clinical policy guidelines specifically recommend IV valproate as a Level B option for refractory status epilepticus 2.
Status Epilepticus Dosing
- Loading dose: 20-30 mg/kg IV at rates of 40 mg/min (or up to 6-10 mg/kg/min for rapid loading) 2
- Studies show 66-88% efficacy in controlling seizures 2
- Advantages over phenytoin: Can be given more quickly with fewer adverse effects, particularly less hypotension (0% vs 12% with phenytoin) 2
Acute Mania
IV valproate loading is effective for acute manic episodes in bipolar disorder:
- Same loading dose: 20 mg/kg IV, followed by oral maintenance 3, 4, 5
- Leads to more rapid symptom improvement compared to oral maintenance dosing alone 5
- Both IV and oral loading achieve similar efficacy, but IV may be preferred when oral administration is not feasible 4, 5
Safety Profile
Rapid IV administration (up to 10 mg/kg/min at doses up to 30 mg/kg) is safe and well-tolerated 6. Key safety points:
- Minimal cardiovascular effects: No significant changes in heart rate or blood pressure 6
- No respiratory depression (unlike phenobarbital or propofol) 2
- Transient local irritation may occur but resolves within 3 minutes 6
- Common side effects: dizziness, thrombocytopenia, potential liver toxicity, hyperammonemia 2
Practical Considerations
The absolute bioavailability of oral Depakote ER is approximately 90% relative to IV infusion 1, making conversion between formulations straightforward. When switching from IV to oral:
- Oral maintenance can begin 2-6 hours after IV loading dose 7
- Extended-release formulations can be initiated concurrently with IV loading 7
- Therapeutic range: 50-100 mcg/mL for epilepsy, 85-125 mcg/mL for mania 1
Common Pitfall
Don't confuse the brand names—clinicians often say "IV Depakote" colloquially, but the actual product name is Depacon. Both contain valproate and are clinically equivalent once administered.